TRXB - TRex Bio, Inc.
SNF Emerging Watchlist(TM) tracks newly public companies positioned around emerging economic themes. Inclusion reflects SNF research interest and ongoing monitoring; it is not a recommendation to buy, sell, or hold a security.
TRexBio is developing immunoregulatory medicines around tissue Treg biology. TRB-061 established Phase 1a proof of mechanism and moved into patient testing, while Lilly's partnered program adds external validation. Candidate status reflects credible biology and funding, with patient-level efficacy still to be proven.
Added to SNF Emerging Watchlist as a Candidate after the October 2026 review incorporated TRB-061 Phase 1a data, Phase 1b execution, the Lilly partnership and post-IPO runway.
Selective activation of regulatory T cells could address underlying immune dysregulation across multiple inflammatory diseases. TRexBio now has enough clinical and strategic evidence to monitor formally.
Market Confirmation begins at 50/100 because TRXB has only a short public trading history. Initial price performance contributes zero Emerging Score points.
Mid-2027 atopic-dermatitis data showing meaningful efficacy with clean safety would strengthen the thesis. Weak patient benefit, safety issues or delays would weaken it.